Landscape Capital Management L.L.C. Acquires Shares of 31,448 Guardant Health, Inc. (NASDAQ:GH)

Landscape Capital Management L.L.C. acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 31,448 shares of the company's stock, valued at approximately $721,000.

Several other large investors also recently added to or reduced their stakes in the business. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Guardant Health by 1,282.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock worth $28,128,000 after buying an additional 1,137,482 shares during the last quarter. First Light Asset Management LLC raised its position in Guardant Health by 119.7% during the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company's stock valued at $12,042,000 after purchasing an additional 227,202 shares in the last quarter. International Assets Investment Management LLC lifted its stake in Guardant Health by 2,193.9% during the third quarter. International Assets Investment Management LLC now owns 10,208 shares of the company's stock worth $2,340,000 after purchasing an additional 9,763 shares during the last quarter. Sei Investments Co. bought a new stake in Guardant Health in the 2nd quarter worth approximately $831,000. Finally, SG Americas Securities LLC purchased a new stake in Guardant Health in the third quarter worth approximately $1,029,000. Institutional investors own 92.60% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on GH. Craig Hallum lifted their price objective on Guardant Health from $28.00 to $37.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. Piper Sandler boosted their price objective on Guardant Health from $30.00 to $34.00 and gave the company an "overweight" rating in a research report on Tuesday, August 13th. Citigroup lifted their target price on shares of Guardant Health from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Finally, Leerink Partners lowered their price objective on shares of Guardant Health from $60.00 to $50.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.60.

Guardant Health Stock Performance

Shares of GH traded up $1.67 during mid-day trading on Friday, hitting $32.65. 2,170,329 shares of the company traded hands, compared to its average volume of 2,280,047. The stock has a market cap of $4.03 billion, a price-to-earnings ratio of -7.70 and a beta of 1.11. The stock has a 50-day moving average price of $24.22 and a two-hundred day moving average price of $26.95. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $37.04. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The firm's revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.73) EPS. Equities analysts anticipate that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Insider Buying and Selling

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares in the company, valued at $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.